MedPath

Allopurinol

Generic Name
Allopurinol
Brand Names
Aloprim, Zyloprim
Drug Type
Small Molecule
Chemical Formula
C5H4N4O
CAS Number
315-30-0
Unique Ingredient Identifier
63CZ7GJN5I

Overview

Gout is a disease that occurs by the deposition of monosodium urate crystals (MSU) in body tissues, especially around joints . This disease has been well-documented in historical medical records and appears in the biographies of several prominent, historically recognized individuals . Allopurinol is a xanthine oxidase enzyme inhibitor that is considered to be one of the most effective drugs used to decrease urate levels and is frequently used in the treatment of chronic gout . It was initially approved by the FDA in 1966 and is now formulated by several manufacturers .

Background

Gout is a disease that occurs by the deposition of monosodium urate crystals (MSU) in body tissues, especially around joints . This disease has been well-documented in historical medical records and appears in the biographies of several prominent, historically recognized individuals . Allopurinol is a xanthine oxidase enzyme inhibitor that is considered to be one of the most effective drugs used to decrease urate levels and is frequently used in the treatment of chronic gout . It was initially approved by the FDA in 1966 and is now formulated by several manufacturers .

Indication

Allopurinol is indicated in : 1) the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy). 2) the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment with allopurinol should be discontinued when the potential for overproduction of uric acid is no longer present. 3) the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients. Therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks.

Associated Conditions

  • Hyperuricemia
  • Primary Gout
  • Recurrent calcium oxalate calculi
  • Secondary gout
  • Calcium oxalate calculi Renal Calculi

FDA Approved Products

Allopurinol
Manufacturer:Cardinal Health 107, LLC
Route:ORAL
Strength:100 mg in 1 1
Approved: 2021/07/26
NDC:55154-2338
Zyloprim
Manufacturer:Contract Pharmacy Services-PA
Route:ORAL
Strength:300 mg in 1 1
Approved: 2018/02/24
NDC:67046-681
Allopurinol
Manufacturer:Preferred Pharmaceuticals Inc.
Route:ORAL
Strength:100 mg in 1 1
Approved: 2023/06/14
NDC:68788-8458
Allopurinol
Manufacturer:Bryant Ranch Prepack
Route:ORAL
Strength:100 mg in 1 1
Approved: 2023/05/26
NDC:71335-1656
Allopurinol
Manufacturer:Unichem Pharmaceuticals (USA), Inc.
Route:ORAL
Strength:100 mg in 1 1
Approved: 2024/02/09
NDC:29300-349

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath